Isavuconazonium Sulfate Structural Formula (Image 01)
Cresemba Capsule
Product Images NDC 0469-0520
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Cresemba (NDC 0469-0520). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Astellas Pharma Us, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1. The Effect Of Co-administered Drugs On Isavuconazole Exposure (Image 02)
This appears to be a list of medications along with dosages (Ketoconazole, LopinavirRitonavr, Rifampin, and Esomeprazole) and some measurements (AUC and MD). Without any context or additional information, it is not possible to provide a useful description.*
Figure 2. The Effect Of Isavuconazole On Co-administered Cyp3a4 Substrate Medications (Image 03)
This is a list of drugs and their doses, including CYP3a substrates, such as Ritonavir, Lopinavir, Prednisone, Ethinyl Estradiol, Norethindrone, Cyclosporin, Atorvastatin, and Midazolam. The table also has columns showing the ratio relative to substrate alone and 90% confidence intervals. No further information is available.*
Figure 3. The Effect Of Isavuconazole On Exposure Of Co-administered Cyp Substrate Medications (Image 04)
This appears to be a table showing the effect of various substances (Bupropion, Repaginide, etc.) on different substrates (CYeiR2, cvp2Bersas, etc.) with different dosages (100 mg, 5mg, etc.). There is also information about ratios and 90% confidence intervals. It's unclear what the substrates and substances are used for or what the data represents.*
Figure 4. The Effect Of Isavuconazole On Exposure On The Substrates Of Ugt And Transporters (Image 05)
Cresemba (isavuconazonium Sulfate) Capsules 186 mg Blister Carton Label (Image 06)
This is an information insert for Cresemba 186 mg (isavuconazonium sulfate) capsules, which are equivalent to 100 mg isavuconazole. The dosage information is not provided and the user is advised to check the prescribing information. The capsules must be swallowed whole and not chewed or dissolved. The medication can be taken with or without food and must be kept in its original package to protect it from moisture until ready to be taken. The capsule contains isavuconazonium sulfate 186 mg. The user can contact 1-800-727-7003 or visit www.cresemba.com for patient information. The medication must be stored at 20-25°C (68-77°F) and out of the reach of children. NDC 0469-0520-02 is provided.*
Image 07
Cresemba is a prescription injection drug containing isavuconazonium sulfate, equivalent to 200mg of isavuconazole. It is used for intravenous infusion only with an in-line filter during administration. The unused portion should be discarded, and the drug should be stored refrigerated at 2° to 8°C. Cresemba is marketed and distributed by Astellas Pharma US, Inc. and is a trademark of Astellas US LLC.*
Image 08
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
